Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lipid encapsulated cisplatin - LiPlasome Pharma

Drug Profile

Lipid encapsulated cisplatin - LiPlasome Pharma

Alternative Names: LiPlaCis

Latest Information Update: 06 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LiPlasome Pharma
  • Developer Cadila Pharmaceuticals; LiPlasome Pharma; Oncology Venture A/S
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Prostate cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 04 Jun 2019 The US FDA provides its initial response to the IND application and proposed pivotal phase III study in the US, requesting additional testing of LiPlaCis® related to the product characterization
  • 18 Dec 2018 Oncology Ventures plans to file an application for Breakthrough designation for breast cancer
  • 18 Dec 2018 Oncology Ventures announces intention to submit IND application to the US FDA for phase III in Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top